Risks of Expired Patents for Businesses

The biopharma industry has ~$200B in revenue at risk in the next 5 years, including 8 out of the top 15 drugs. Here's a closer look behind the upcoming patent cliff: The question of "when will a drug face competition" is incredibly complex to answer. There are many factors at play - patents, lawsuits, and the type of drug, among many others. Legally, drugs have two main forms of protection - exclusivity and patents: In the US, the period of exclusivity depends largely on the type of drug - drugs containing a new chemical entity (NCE) have 5 years of exclusivity. Meanwhile, more complex biologic drugs get 12 years, thanks to the BPCIA. A key difference between exclusivity and patents is that while patents can be granted at any time during the innovation process, exclusivity is granted upon approval of the drug, if requirements are met. Some drugs are protected by both patents and exclusivity at the same time, and some by just one or the other. Patents technically last 20 years. However, as with many things in biopharma, the story isn't that simple: by the time a drug is approved by the FDA and launched, several of those years will have expired, leaving roughly 10-12 years left on the patent. Eli Lilly's GLP-1 blockbuster Zepbound is a good example: it launched late last year, but its US patents expire in 2036 - 13 years away. But expiration dates of key patents only tell part of the story, as there are a variety of factors that can delay the arrival of competition. While primary patents may expire, companies often have additional IP, like formulation patents, that extend the timeline. Regeneron's Eylea is a case in point - composition of matter patents expired in 2023, but formulation patents last until 2027, and the company recently won a lawsuit against a would-be generic challenger, Viatris. Additionally, companies often strike commercial settlements with generics manufacturers. J&J's Stelara is a good example. Key US patents for Stelara expired in 2023, but J&J struck settlements that delayed likely competition until 2025. While patent cliffs pose challenges, the complexity reveals a key insight: Navigating the patent cliff is less about the fall, and more about the parachute - a blend of legal acumen, strategic patents, and timely settlements ensure things aren't as dire as they might seem.

When Alex Levin and I pitch PioneerIP, we touch on the important topic of small mistakes. In the world of #IP, the smallest misstep can carry the weight of billions. Take Novo Nordisk. The company behind #Ozempic and Wegovy holds one of the most valuable pharmaceutical portfolios of our time. Yet, amid lawsuits, compounding loopholes, and global shortages, a far quieter event occurred: a patent expired in Canada. Not because of litigation. Not because of innovation. Because of a missed administrative fee. Take a look at the insightful article https://lnkd.in/gJV3aJqQ in the Financial Times. That oversight opened the door for generics in 2026. A single clerical lapse, and the monopoly that underpins years of R&D begins to erode. This is the paradox of patent maintenance. On one hand, corporations wage high-stakes battles in courtrooms, defending exclusivity against distributed networks of infringers. On the other, they risk everything through the mundane — renewal deadlines, annuity payments, and jurisdictional complexity. The strength of a patent isn’t just written in its claims. It’s in the rigour of its upkeep. And here’s the twist: #enforcement and #maintenance aren’t separate challenges. They are deeply connected. The value of maintaining a patent depends on the real, measurable threat of infringement. Why pay millions in fees across dozens of markets if the underlying rights can’t be defended — or worse, won’t generate meaningful return? At PioneerIP, we believe companies should never face this decision in the dark. Our infringement intelligence platform provides clarity: - Where and how your patents are at risk. - What revenue streams are truly protected. - And how those insights should shape maintenance decisions. As corporations prepare for their 2026 budgets, the urgency is clear. Our clients share that IP departments are being asked to do more with less. CFOs want leaner IP portfolios. General counsel want defensible assets. CEOs want certainty. The question is no longer simply: Should we renew this patent? The real question is: Do we know what we risk if we don’t? Novo Nordisk’s story is a cautionary tale, but also an invitation. A reminder that in today’s climate — with compounding pharmacies, cross-border loopholes, and political pressure on pricing — the companies that thrive will be those that maintain with foresight, not inertia. This budget season, don’t just renew. Reassess. Refocus. Realign maintenance with enforcement value.

A $200 billion "patent cliff" is looming over the pharmaceutical industry. For the uninitiated, it looks like a routine legal expiration. For Wall Street, it is a definitive signal to sell. The problem is systemic. When a blockbuster drug loses exclusivity, revenue doesn't just dip—it evaporates. Generic competitors often capture 90% of market share within weeks. This creates a vacuum in the balance sheet that even the most robust pipelines struggle to fill. Investors hate uncertainty. Without precise data on patent expiration dates, financial modeling becomes mere guesswork. The agitation lies in the volatility. One court ruling on a secondary patent can swing a market cap by billions in a single afternoon. Analysts who miss these dates aren't just late; they are obsolete. They watch helplessly as portfolios bleed value because they failed to track the "evergreening" tactics of Big Pharma. The solution is the strategic integration of patent expiry data into fundamental analysis. Sophisticated analysts now treat patent landscapes as the primary lead indicator for stock movement. They map out the "loss of exclusivity" (LOE) years in advance. They don't just look at the primary patent. They deconstruct the entire patent thicket—formulations, dosages, and manufacturing processes. This data allows for the calculation of "revenue at risk" with surgical precision. It transforms a legal deadline into a predictable financial event. In a sector driven by innovation, the most valuable asset isn't the science—it’s the clock. Knowing exactly when that clock stops is the only way to safeguard alpha in an increasingly crowded market. Precision in patent tracking is no longer a luxury. It is the price of entry. #Pharmaceuticals #Patents #Generics https://lnkd.in/eDZK5vr7

The Impending Pharma Patent Cliff: A $200B+ Shift in the Healthcare Landscape The pharmaceutical industry is approaching a massive "Patent Cliff." Over the next decade, some of the world’s most successful blockbuster drugs—from Keytruda to Eliquis—will lose their market exclusivity. Why This Matters Now When a patent expires, the "cliff" refers to the sharp decline in revenue for the original manufacturer as generic and biosimilar competitors enter the market. Based on 2023 sales data, the financial stakes are staggering: 2028: The Year of the Giant. Merck’s Keytruda, currently sitting at a $25B valuation, is set to face competition. 2026: The Cardiovascular Shift. Bristol Myers Squibb and Pfizer’s Eliquis ($12.2B) will see its exclusivity end. 2032: The Metabolic Wave. The GLP-1 revolution faces its own cliff with Ozempic ($18.4B) losing protection. Two Sides of the Transformation For Innovation: This pressure forces Big Pharma to accelerate R&D. We are seeing a surge in M&A activity and a pivot toward complex biologics and personalized medicine to fill the upcoming revenue gaps. For Access: For healthcare systems and patients, this transition typically means significantly lower costs and broader access to life-saving therapies. The next few years won't just be about losing revenue; they will be about who can innovate fast enough to define the next era of medicine. How do you see the industry evolving to mitigate these losses? Is the "biologic moat" enough to protect future portfolios? #Pharmaceuticals #Vskinsights #HealthcareInnovation #Biotech #MarketTrends #PatentCliff #PharmaStrategy #DrugDevelopment #HealthEconomics